About Careers Internship MedBlog Contact us

Biosimilar Version of Remicade for Autoimmune Diseases Likely to Get FDA Approval

by Reshma Anand on February 10, 2016 at 4:17 PM
Biosimilar Version of Remicade for Autoimmune Diseases Likely to Get FDA Approval

Remsima could soon become the second biosimilar drug to be approved by the U.S. Food and Drug Administration.

Biosimilar drugs are drugs made from living cells and are relatively cheaper than generic medicines. They function similar to its generic drug and helps to cure ailments.


Remsima is a biosimilar drug of Johnson & Johnson's Remicade. Remicade helps in the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Remsima has been developed by South Korea's Celltrion and co-marketed with Pfizer. The drug was tested for arthritis and trials against bowel diseases are being conducted by the company.

Now the FDA panel has voted 21-3 for the biosimilar drug, supporting its approval on April 6. There are objections from the J&J company due to its on-going trials against bowel diseases.

The statement from J&J reads that, "We believe that the data to date, absent of direct comparisons of CT-P13 and REMICADE in patients with inflammatory bowel disease, leave uncertainty about whether differences in safety or efficacy may emerge for patients," said Jay Siegel, M.D., Chief Biotechnology Officer and Head, Scientific Strategy and Policy at Johnson & Johnson.

"We appreciate the discussions at today's hearing, and note that some of the advisors—who voted on either side of the question—share our concerns regarding residual uncertainty about the use of CT-P13 in IBD. We hope that FDA carefully considers our detailed written testimony," he added.

But the FDA has recommended the biosimilar drug to be approved for treating autoimmune diseases similar to that of the drug Remicade. The drug will be priced lesser to that of its original drug.

The first biosimilar drug approved by the FDA was Zarzio. It is a version of Amgen's Neupogen, which boosts white blood cells in patients who have undergone chemotherapy.

Source: Medindia
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Biosimilar Version of Remicade for Autoimmune Diseases Likely to Get FDA Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests